Dr. Celine Gounder joins CBS Mornings to break down the FDA-approved drug Lenacapavir, which is being called the closest step ...

The Food and Drug Administration has approved a drug that reduces the chances of contracting HIV. A University of Utah ...

Yeztugo, approved by the FDA, was highly effective in two randomized trials. It costs $28,218 per year, and people have to be ...

Clinical trials showed 99.9% of participants who received the drug, called Yeztugo​ from company Gilead Sciences, remained ...

Yeztugo, a twice-a-year antiviral shot to prevent HIV, was approved by the Food and Drug Administration on Wednesday, marking ...

The Food and Drug Administration has approved a new drug that could prevent HIV infections with just two shots every year and ...

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug ...

In clinical trials, researchers found Yeztugo to be highly effective as a twice-yearly form of pre-exposure prophylaxis.

HealthLink talked with a Seattle-based physician about why the newly approved drug could be a game-changer in preventing HIV.

Lenacapavir, the injectable drug developed by a US-based company, Gilead Sciences, was trialled (tested) in Uganda and South ...

Analysts believe that Gilead's new PrEP drug Yeztugo could reach peak sales of $4.5 billion. Not if GSK has anything to say about it.

WASHINGTON -- The U.S. has approved the world’s only twice-a-year shot to prevent HIV, maker Gilead Sciences announced ...